Islet transplantation for type 1 diabetes - Where should we go?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 1, 2007, Pages 2-3

  Witkowski, Piotr ^a,b   Herold, Kevan C ^c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELATACEPT; C PEPTIDE; CALCINEURIN INHIBITOR; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RECOMBINANT HUMAN INSULIN; TACROLIMUS;

ALBUMINURIA; ALLOTRANSPLANTATION; BLEEDING; DIABETOGENESIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT REJECTION; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MACROALBUMINURIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDICAL PRACTICE; MICROALBUMINURIA; NEPHROTOXICITY; PANCREAS ISLET TRANSPLANTATION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS TRANSPLANTATION; PANCREAS TRANSPLANTATION; TISSUE DONORS;

EID: 33845778584     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0369     Document Type: Short Survey

References (10)

1. Shapiro AM et al. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343: 230-238
2. Collaborative Islet Transplant Registry Annual Reports [https://web.emmes.com/study/isl/reports/reports.htm] (accessed 12 November 2006)
3. Poggioli R et al. (2006) Quality of life after islet transplantation. Am J Transplant 6: 371-378
4. Ryan EA et al. (2005) Five-year follow-up after clinical islet transplantation. Diabetes 54: 2060-2069
5. Steffes MW et al. (2003) Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26: 832-836
6. Hafiz MM et al. (2005) Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation 80: 1718-1728
7. Pyzdrowski KL et al. (1992) Preserved insulin secretion and insulin independence in recipients of islet autografts. N Engl J Med 327: 220-226
8. De Leon DD et al. (2003) Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 52: 365-371
9. Hering BJ et al. (2004) Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 4: 390-401
10. Dombrowski F et al. (2006) Hepatocellular neoplasms induced by low-number pancreatic islet transplants in autoimmune diabetic BB/Pfd rats. Cancer Res 66: 1833-1843